Inovio Pharmaceuticals (INO) analyst forecast and price target
Analyst forecast
Consensus of 3 analyst ratings
Based on 3 analyst targets
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| Jefferies | Upgraded | Hold → Buy | $3.00 from $1.80 | Aug 13, 2026 |
| Piper Sandler | Maintained | Overweight | $4.00 from $6.00 | Aug 3, 2026 |
| HC Wainwright & Co. | Maintained | Neutral | $2.50 from $3.00 | Jun 1, 2026 |
| Piper Sandler | Maintained | Overweight | $6.00 from $5.00 | Nov 14, 2025 |
| HC Wainwright & Co. | Maintained | Neutral | $3.00 | Aug 14, 2025 |
| Piper Sandler | Initiated Coverage | Overweight | $5.00 | Jul 9, 2025 |
| Oppenheimer | Maintained | Outperform | $13.00 from $15.00 | May 14, 2025 |
| RBC Capital | Maintained | Sector Perform | $5.00 | May 14, 2025 |
| HC Wainwright & Co. | Maintained | Neutral | $3.00 | Mar 19, 2025 |
| RBC Capital | Maintained | Sector Perform | $5.00 from $6.00 | Mar 19, 2025 |
| Citizens Capital Markets | Maintained | Market Outperform | $18.00 | Mar 14, 2025 |
| HC Wainwright & Co. | Maintained | Neutral | $3.00 from $5.00 | Jan 13, 2025 |
| JMP Securities | Maintained | Market Outperform | $18.00 | Jan 10, 2025 |
| Oppenheimer | Maintained | Outperform | $15.00 from $33.00 | Nov 18, 2024 |
| HC Wainwright & Co. | Maintained | Neutral | $5.00 from $12.00 | Nov 18, 2024 |
| RBC Capital | Maintained | Sector Perform | $6.00 from $7.00 | Nov 15, 2024 |
| RBC Capital | Maintained | Sector Perform | $7.00 from $8.00 | Oct 4, 2024 |
| Oppenheimer | Maintained | Outperform | $33.00 from $40.00 | Aug 12, 2024 |
| RBC Capital | Maintained | Sector Perform | $8.00 from $11.00 | Aug 9, 2024 |
| HC Wainwright & Co. | Maintained | Neutral | $15.00 | Jul 15, 2024 |
Frequently asked questions
What is the price target for INO stock?
The average 12-month analyst price target for Inovio Pharmaceuticals (INO) is $3.17, with a high estimate of $4.00 and a low of $2.50, across 3 analysts.
Is INO a buy, sell, or hold?
Analysts covering Inovio Pharmaceuticals currently average a Buy rating: 2 buy, 1 hold and 0 sell, from 3 analysts. Ratings reflect analyst opinion, not investment advice.
What upside do analysts see for INO?
The average price target of $3.17 implies 149.34% upside from the last price of $1.27.
What is the latest analyst rating on INO?
On Aug 13, 2026, Jefferies upgraded Inovio Pharmaceuticals to Buy with a price target of $3.00.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.